Genitourinary Cancer Program

Prostate cancer is the second-most diagnosed cancer among men in the United States. City of Hope Atlanta offers patients access to innovative radiopharmaceutical treatments like Pluvicto^® (lutetium Lu 177 vipivotide tetraxetan). When combined with drugs that bind to and help detect prostate cancer lesions expressing prostate-specific membrane antigen (PSMA), Pluvicto can target and destroy prostate cancer cells.

At City of Hope, our physicians and clinical staff have decades of experience diagnosing and treating multiple types and all stages of cancer affecting the urinary tract and male reproductive system, including bladder, kidney, prostate and testicular cancers, as well as relapsed and refractory disease.

We offer a comprehensive range of services, including:

• State-of-the-art robotic and open surgery
• Robot-assisted laparoscopic radical prostatectomy
• Robot-assisted radical cystectomy with urinary diversion
• Kidney cancer surgery
• Testicular cancer surgery
• Penectomy or partial penectomy for penile cancer
• Inguinal node dissection for penile cancer
• Transurethral resection of bladder tumors
• Ultrasound-guided transperineal prostate biopsy
• Blue light cystoscopy
• Radioligand therapy
• Genomic and genetic testing
• State-of-the-art diagnostics
• Chemotherapy
• Immunotherapy
• External beam radiation therapy
• High–dose–rate (HDR) brachytherapy
• Access to clinical trials and studies
• Fertility-sparing options for certain patients
• Survivorship support for all patients
• Supportive care, including dietary support, behavioral health services, occupational therapy and sexual wellness counselling

Treatment offerings may vary by location.

The genitourinary cancers we treat are wide and varied. They include all stages and types of:

• Prostate cancer
• Bladder cancer
• Renal cell carcinoma (kidney cancer, all histologic subtypes)
• Testicular cancer
• Penile cancer
• Adrenal cancer
• Primary urethral carcinomas
• Pheochromocytoma

Patients referred to City of Hope Atlanta for genitourinary cancer care work closely with a multidisciplinary team that may include surgeons, medical and radiation oncologists, interventional radiologists, supportive care team members and other trained professionals. Below are some of the key members of the genitourinary cancers team.

City of Hope has a longstanding history as a leader in both cancer treatment and breakthrough research that has led to many new therapies that are now standard-of-care options in the field of oncology. Some of our institution’s distinctions include:

• A nationally recognized leader in genitourinary cancer care, founded on more than a century of expertise in providing leading-edge treatment for a wide range of life-threatening diseases
• A national network of comprehensive cancer centers and outpatient locations, offering the ability to deliver groundbreaking, often-lifesaving care for our patients through collaboration between physicians and experts across the country
• Surgical oncology expertise, with physicians who have performed more than 11,000 robotic procedures that offer surgical precision, reduced postoperative pain and more rapid recovery
• Reconstructive surgery expertise for patients whose cancer treatment requires reconstructing the appearance and function of the genitourinary tract
• One of the first cancer centers in the United States to conduct robotic-assisted prostatectomy using the da Vinci^® Surgical System, starting in 2003
• Accelerated access to new therapies, thanks to a bench-to-bedside approach powered by three state-of-the-art, good manufacturing practice- (GMP-)certified facilities
• A diverse portfolio of clinical trials focused on genitourinary cancers, including studies investigating both immunotherapy and stem cell treatment options

City of Hope Atlanta’s genitourinary program includes a dedicated multidisciplinary team that blends innovative research discoveries with leading-edge treatments. Since genitourinary diseases may frequently be treated by multiple modalities, deliberate collaboration is needed between physicians and advanced practice providers to optimize clinical outcomes. The result is improved outcomes for patients with genitourinary cancers. Our program is also:

• Certified by the American Society of Clinical Oncology Quality Oncology Practice Initiative Certification Program, which is awarded to hospitals that demonstrate a commitment to quality along nationally approved standards
• Accredited by the College of American Pathologists, including recognition for biorepository services for tissue collection, preparation, sampling and processing at our laboratory, making it one of fewer than 100 such sites in the United States
• Given the 5-star rating for patient experience from the Centers for Medicare and Medicaid Services (2025)
• Named an Accreditation Program for Excellence^® (APEx) by American Society of Radiation Oncology (ASTRO) for providing high-quality and safe radiation care to patients
• Accredited by the American College of Radiology, which evaluates radiation programs on its clinical operations, treatment delivery, patient outcomes and quality assurance